Pioglitazone and the glitazones: heart failure, liver checks and patient teaching

How glitazones work and why the onset is slow

Pioglitazone is the thiazolidinedione most nurses will see. It improves insulin sensitivity in muscle, fat and liver rather than stimulating insulin release, so on its own it is not expected to cause hypoglycaemia. It is used for type 2 diabetes only and is not a treatment for type 1 diabetes or diabetic ketoacidosis.

Glucose begins to fall over the first couple of weeks, but the full effect can take two to three months. Patients who expect a quick change may stop the tablet or double up. Explain the timeline at the start, and interpret early glucose readings in light of it rather than concluding the drug has failed after a few days.

Fluid retention and the heart failure warning

Thiazolidinediones cause fluid retention, which can lead to or worsen heart failure. The label contraindicates starting pioglitazone in established severe heart failure and advises monitoring after starting or increasing the dose. Using it with insulin increases the fluid retention risk. Weight gain is common, and some of it reflects retained fluid rather than fat.

Assess for rapid weight gain, ankle swelling, breathlessness on exertion or lying flat, waking breathless at night and new crackles. Report these before the next dose; the prescriber decides whether to stop. A rise in weight over a few days points to fluid, while slow gain over months is more consistent with tissue gain.

Escalation is more urgent when the patient already has heart disease, kidney impairment or a history of heart failure, or when the dose was recently increased. In hospital, daily weights on the same scale, intake and output, and a respiratory assessment before the dose are reasonable ways to pick up early fluid retention rather than waiting for overt breathlessness.

Liver, bone, eye and bladder warnings

Baseline liver tests are obtained before starting. Teach patients to stop and seek advice for nausea, vomiting, loss of appetite, right upper abdominal pain, dark urine or yellowing of skin or eyes, and report these findings promptly, because the label advises stopping if significant liver injury is suspected.

Fractures, mostly of the hands, arms and feet, occur more often in women taking pioglitazone, so ask about falls and bone health. Macular oedema has been reported, so report blurred or reduced vision and keep eye checks up to date. The drug may raise bladder cancer risk and should not be used with active bladder cancer; report blood in the urine or urgency.

Interactions and teaching that change behaviour

Hypoglycaemia becomes a risk when pioglitazone is combined with insulin or a sulfonylurea, so teach recognition and treatment of low glucose and monitor more often when doses change. In premenopausal women with irregular cycles, the drug may restore ovulation, so discuss contraception if pregnancy is not planned.

Good teaching links each warning to something the patient can notice: weigh at the same time each day, look for swollen ankles, notice new breathlessness, watch urine colour and vision. Ask for teach-back using a realistic example, such as what they would do if their weight jumped and their shoes felt tight.

Worked scenario: weight gain on pioglitazone and insulin

A hypothetical patient with type 2 diabetes started pioglitazone alongside insulin a month ago. Today their weight is up three kilograms in five days, both ankles are swollen and they need two pillows to sleep. Options include advising a lower-calorie diet, giving the dose because glucose has improved, or holding and reporting.

Holding and reporting is correct. Rapid gain with oedema and orthopnoea suggests fluid retention progressing towards heart failure, the boxed warning, and the insulin combination increases that risk. Diet advice treats the wrong cause, and improved glucose does not make a heart failure sign acceptable. The prescriber reviews the drug while the nurse completes a cardiorespiratory assessment.

Sources and further reading

DailyMed: Pioglitazone tablets prescribing information. Boxed heart failure warning, fluid retention with insulin, baseline liver tests, bladder cancer, fractures, macular oedema and ovulation.

MedlinePlus: Pioglitazone. Insulin sensitising action, onset timeline, heart failure and liver warning signs, hypoglycaemia with combinations.